HomeESPR • NASDAQ
add
Esperion Therapeutics Inc
Previous close
$2.47
Day range
$2.45 - $2.54
Year range
$1.16 - $3.40
Market cap
496.53M USD
Avg Volume
4.40M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 51.63M | 52.00% |
Operating expense | 39.98M | 20.26% |
Net income | -29.52M | 28.43% |
Net profit margin | -57.18 | 52.91% |
Earnings per share | -0.15 | 59.46% |
EBITDA | -16.00M | 41.83% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 144.72M | 26.02% |
Total assets | 314.11M | 41.94% |
Total liabilities | 684.32M | 8.40% |
Total equity | -370.21M | — |
Shares outstanding | 197.04M | — |
Price to book | -1.31 | — |
Return on assets | -12.02% | — |
Return on capital | 45.44% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -29.52M | 28.43% |
Cash from operations | -35.32M | -82.79% |
Cash from investing | -167.00K | — |
Cash from financing | -9.10M | -110.92% |
Net change in cash | -44.59M | -88.63% |
Free cash flow | -32.60M | -91.85% |
About
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. Wikipedia
Founded
May 1998
Website
Employees
240
